Key facts
- This page summarizes Teri L. Lawver's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Nov 2025, 16:12.
Teri L. Lawver - 10 Nov 2025 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)
- Reporting relationship
- SVP & Chief Commercial Officer
- Issuer ticker
- CLDX
- Reported as of
- 10 Nov 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Nov 2025, 16:12:27 UTC
- Prior SEC filing
- 29 Sep 2025
- Next SEC filing
- 01 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sam Martin, attorney-in-fact for Teri Lawver
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Teri L. Lawver filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 12 Nov 2025.
Change
- Previous filing in this sequence was filed on 29 Sep 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001960596
Primary reporting owner
Lawver Teri L
- Relationship
- SVP & Chief Commercial Officer
- Address
- C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON
- Signature
- /s/ Sam Martin, attorney-in-fact for Teri Lawver
- Signature date
- 12 Nov 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDX
transaction
Derivative
ISO (right to buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 10 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $22.67
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Footnote F2
25% vest on November 10, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.